Nikola Trbovic is a principal at Pfizer Ventures, Pfizer’s corporate venture capital unit with responsibility for the US-based drugs group’s investments in Arrakis, Artios, Cydan, Jnana, Nimbus and Palleon.
Pfizer Ventures was formed at the beginning of 2018 to integrate all of Pfizer’s equity investment activities under one team.
Barbara Dalton, head of Pfizer Ventures, said: “Nikola is one of the new members of Pfizer Ventures having joined full time earlier this year. He brought the experience he gained over the previous three years working part time with Pfizer’s R&D Innovate initiative (that has since been rolled into Pfizer Ventures). This permitted him to jump in to be the internal lead for the investment we recently closed in Artios.
“Throughout that process he demonstrated several skills necessary for success in this business – intellect, strategic thinking, humility and people skills. Combined those traits supported building personal relationships while at the same time solving problems and learning a lot in the process. I am sure that as more members of the venture community get to know Nikola they too will be impressed. He has a great future in our business and I am excited to be working with him at the beginning of his career.”
Trbovic added: “My greatest success so far has probably been the impact I have had on setting up the R&D Innovate initiative – a $25m a year expansion of the CVC activities at the time dedicated to highly strategic investment opportunities – the success of which was a big part of our ability to argue for the integration and further expansion of Pfizer’s CVC activities earlier this year.”
